Nov 6, 2023
|
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
|
Nov 3, 2023
|
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
|
Oct 31, 2023
|
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
|
Oct 30, 2023
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Oct 23, 2023
|
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
|
Oct 18, 2023
|
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
|
Oct 17, 2023
|
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
|
Oct 17, 2023
|
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
|
Oct 13, 2023
|
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
|
Oct 4, 2023
|
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
|